Objective: To report a case of ovarian hyperstimulation syndrome with methylenetetrahydrofolate reductase (MTHFR) gene 677T homozygosis mutation and A1298C gene heterozygosis mutation.
Design: Case report.
Setting: A pregnant woman in an academic hospital.
Patient(s): A woman with ovarian hyperstimulation syndrome.
Intervention(s): Nadroparin was administered for 2 weeks at a dosage of 200 IU/kg twice per day and then once per day; also administered once per day were folates, 5 mg; B6 vitamin, 15 mg; and B12 vitamin, 1 mg.
Main outcome measure(s): Clinical follow-up.
Result(s): Delivery was regular within the set time limits, and the fetus was born alive and in good health.
Conclusion(s): We believe that MTHFR mutation research could be executed in women before ovarian stimulation treatment, but other observations are necessary to support this recommendation.